Plus Therapeutics to Participate in Upcoming January Conferences
AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck...
BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential...
ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant...
NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced...
Conference Begins on January 10, 2022RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company,...
Delisting of AS "Olainfarm” shares from the Baltic Main list With this AS "Olainfarm” informs, that Nasdaq Riga decided on January...
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information...
Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) Translational studies performed at...
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV...
Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, January 07, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage...
Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME)...
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug...
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing...
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing...
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that he will be examining...
SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to...
Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of...
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in...